Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

The aim was to study the clinical and microbiological features associated with a carbapenem-resistant Klebsiella pneumoniae isolate that had been selected in vivo by an ertapenem-containing regimen in a patient with mediastinitis despite high blood and mediastinal levels of ertapenem. Carbapenem resistance was characterized by conjugation, PCR, DNA sequencing and analysis of outer-membrane proteins. The isolates susceptible and resistant to the carbapenems were compared by ribotyping and PFGE. Resistance to all available beta-lactams was most probably due to combined production of extended-spectrum beta-lactamase (ESBL) CTX-M-15 and loss of OmpK36 porin. The results of ribotyping and PFGE suggest that the carbapenem-resistant strain was a derivative of the original mediastinal isolate rather than a superinfecting isolate. This observation stresses the risk of selection of pan-penem resistant strains of enterobacteria when ertapenem is used for the treatment of severe infections due to ESBL-producing enterobacteria.

[1]  D. Landman,et al.  Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. , 2009, Journal of medical microbiology.

[2]  Jiachang Cai,et al.  Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. , 2009, Journal of medical microbiology.

[3]  N. Woodford,et al.  Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. , 2009, The Journal of antimicrobial chemotherapy.

[4]  Y. Carmeli,et al.  Ertapenem Resistance among Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae Isolates , 2009, Journal of Clinical Microbiology.

[5]  R. Gesser,et al.  Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. , 2007, American journal of surgery.

[6]  N. Woodford,et al.  In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  H. Teppler,et al.  Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections , 2005, Antimicrobial Agents and Chemotherapy.

[8]  Y. Carmeli,et al.  High Levels of Antimicrobial Coresistance among Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2005, Antimicrobial Agents and Chemotherapy.

[9]  R. Isaacs,et al.  Ertapenem, the first of a new group of carbapenems. , 2003, The Journal of antimicrobial chemotherapy.

[10]  D. Livermore,et al.  Properties and potential of ertapenem. , 2003, The Journal of antimicrobial chemotherapy.

[11]  N. Christou,et al.  Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial , 2003, Annals of surgery.

[12]  J. Hassett,et al.  Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. , 2002, International journal of antimicrobial agents.

[13]  G. Jacoby,et al.  Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[14]  L. Martínez-Martínez,et al.  Porin expression in clinical isolates of Klebsiella pneumoniae. , 1999, Microbiology.

[15]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[16]  H. Boyer,et al.  A complementation analysis of the restriction and modification of DNA in Escherichia coli. , 1969, Journal of molecular biology.

[17]  H. Teppler,et al.  Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study , 2003, Infectious diseases in obstetrics and gynecology.